Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 7/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | MMP1 | P03956 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7627224 | 0.88 | ALDH1A1 (0.72) | GAASMN1; SMN2ALDH1A1KDM4EHPGD | |
| SCHEMBL29614846 | 0.84 | ALDH1A1 (0.67) | GAASMN1; SMN2ALDH1A1KDM4EHPGD | |
| SCHEMBL29658990 | 0.84 | ALDH1A1 (0.67) | GAASMN1; SMN2ALDH1A1KDM4EHPGD | |
| SCHEMBL30960 | 0.81 | GAA (1.00) | GAASMN1; SMN2ALDH1A1KDM4EHPGD | |
| SCHEMBL10448337 | 0.80 | CA1 (0.69) | ALDH1A1TDP1CYP3A4CA1CA2 | |
| SCHEMBL28123632 | 0.80 | CA1 (0.63) | GAASMN1; SMN2ALDH1A1KDM4EHPGD | |
| SCHEMBL4021554 | 0.80 | ALDH1A1 (0.72) | GAASMN1; SMN2ALDH1A1KDM4EHPGD | |
| SCHEMBL10928101 | 0.80 | ALDH1A1 (0.62) | GAASMN1; SMN2ALDH1A1KDM4EHPGD | |
| SCHEMBL28678466 | 0.79 | GAA (0.95) | GAASMN1; SMN2ALDH1A1KDM4EHPGD | |
| SCHEMBL21901012 | 0.79 | GAA (0.63) | GAASMN1; SMN2ALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127728-A1 | MODIFIED GRAPHENE, METHOD OF PRODUCING MODIFIED GRAPHENE, MODIFIED GRAPHENE-RESIN COMPOSITE, MODIFIED GRAPHENE SHEET, AND MODIFIED GRAPHENE DISPERSION | CANON KK (JP) | 2023-04-27 | — | — | US | disclosed |
| EP-3992290-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2022-05-04 | — | — | EP | disclosed |
| WO-2022007866-A1 | FUSED TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | 深圳信立泰药业股份有限公司 | 2022-01-13 | — | — | WO | disclosed |
| EP-3341368-B1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-06 | — | — | EP | disclosed |
| WO-2019195720-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| US-10173997-B2 | Bipyridine compound and use of same for noxious arthropod control | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-01-08 | — | — | US | disclosed |
| EP-2776397-B1 | QUINOLINES AS FGFR KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2017-11-29 | — | — | EP | disclosed |
| WO-2016121969-A1 | BIPYRIDINE COMPOUND AND USE OF SAME FOR NOXIOUS ARTHROPOD CONTROL | 住友化学株式会社 | 2016-08-04 | — | — | WO | disclosed |
| US-9115065-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with Arenaviruses | Kineta, Inc. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9067873-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | Kineta Four, LLC (US) | 2015-06-30 | — | — | US | disclosed |
| US-7994221-B2 | Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | SIGA TECHNOLOGIES, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20110118505-A1 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | SIGA TECHNOLOGIES INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20100256096-A1 | Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | SIGA TECHNOLOGIES, INC. | 2010-10-07 | — | — | US | disclosed |
| CN-101641092-A | Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods of treating hemorrhagic fever viruses, including treatment of arenavirus-associated infections | SIGA TECHNOLOGIES INC US | 2010-02-03 | — | — | CN | disclosed |
| EP-2124921-A2 | SULFONYL SEMICARBAZIDES, CARBONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | SIGA TECHNOLOGIES, INC. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20090203675-A1 | Sulfonyl Semicarbazides, Semicarbazides and Ureas, Pharmaceutical Compositions Thereof, and Methods for Treating Hemorrhagic Fever Viruses, Including Infections Associated with Arena Viruses | SIGA TECHNOLOGIES, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2008147474-A2 | SULFONYL SEMICARBAZIDES, CARBONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | SIGA TECHNOLOGIES, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| EP-1827446-A2 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | SIGA TECHNOLOGIES, INC. (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006062898-A2 | COMPOUNDS AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES | SIGA TECHNOLOGIES, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| US-4892887-A | ANTITUMOR | YALE UNIVERSITY (US) | 1990-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118505-A1 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | SORD, GBA1, GK | GAA 32/4885SMN1; SMN2 1541/4885ALDH1A1 3151/4885 |
| US-20100256096-A1 | Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | GBA1, SORD, GK | GAA 42/4885SMN1; SMN2 1267/4885ALDH1A1 2897/4885 |
| US-20230127728-A1 | MODIFIED GRAPHENE, METHOD OF PRODUCING MODIFIED GRAPHENE, MODIFIED GRAPHENE-RESIN COMPOSITE, MODIFIED GRAPHENE SHEET, AND MODIFIED GRAPHENE DISPERSION | GRIA1, GRIN1, NR3C1 | GAA 2473/4885SMN1; SMN2 930/4885ALDH1A1 593/4885 |
| US-20090203675-A1 | Sulfonyl Semicarbazides, Semicarbazides and Ureas, Pharmaceutical Compositions Thereof, and Methods for Treating Hemorrhagic Fever Viruses, Including Infections Associated with Arena Viruses | GBA1, GK, GCK | GAA 46/4885SMN1; SMN2 932/4885ALDH1A1 1786/4885 |
| US-10173997-B2 | Bipyridine compound and use of same for noxious arthropod control | BBOX1, ACHE, MORF4L1 | GAA 3998/4885SMN1; SMN2 1146/4885ALDH1A1 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.